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Abstract 
The peroxisome proliferator-activated receptor-γ (PPARγ) coactivator 1α (PGC-1α) is a key 
regulator of mitochondrial biogenesis, respiration and adaptive thermogenesis. Beside the 
full-length protein (FL-PGC-1α), several other functionally active PGC-1α isoforms were 
identified as a result of alternative splicing (e.g., N-truncated PGC-1α; NT-PGC-1α) or 
alternative promoter usage (e.g., central nervous system-specific PGC-1α isoforms; CNS-
PGC-1α). The achievement of neuroprotection via the CNS-targeted pharmacological 
stimulation is limited due to the poor penetration of the blood brain barrier (BBB) by the 
proposed pharmaceutical agents, so preconditioning emerged as another option. The current 
study aimed at the examination of how the expression levels of FL-, NT-, CNS- and reference 
PGC-1α isoforms change in different brain regions following various 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) treatment regimens, including the chronic low dose 
treatment for preconditioning. Ninety minutes following the acute treatment regimen, the 
expression level of FL-, NT- and CNS-PGC-1α isoforms increased significantly in the 
striatum, cortex and cerebellum. However, this elevation was diminished 7 days following the 
last MPTP injection in this acute treatment regimen. The chronic low dose administration of 
MPTP, which did not cause significant toxic effect in light of the relatively unaltered 
dopamine levels, neither resulted in any significant change of PGC-1α expression as well. The 
elevation of PGC-1α levels following acute treatment may demonstrate a short-term 
compensatory mechanism against the mitochondrial damage induced by the complex I 
inhibitor MPTP. However, drug-induced preconditioning by chronic low dose MPTP seems 
not to induce protective responses via the PGC-1α system. 
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1. Introduction 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss 
of dopaminergic neurons, and the presence of Lewy bodies in the substantia nigra (SN) pars 
compacta (Forno, 1996). Although the precise pathomechanism of PD is not fully understood, 
several molecular mechanisms of neuronal death were described in the pathogenesis, 
including mitochondrial dysfunction, energy deficit and oxidative stress (Bose and Beal, 
2016). It is postulated that the life-long cumulative low dose exposition to mitochondrial 
toxins may contribute to the pathogenesis of certain neurodegenerative disorders (Harris and 
Blain, 2004). The delineation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
induced Parkinsonian symptoms yielded one of the first evidence that mitochondrial 
dysfunction is involved in PD pathogenesis (Forno et al., 1993). Accordingly, systemic MPTP 
administration have been widely used to study disease mechanisms in various in vivo animal 
studies (Javitch et al., 1985). 
Beside environmental factors, several causative or susceptibility genes have been identified in 
PD, many of them having direct implications in mitochondrial dysfunction (Kalinderi et al., 
2016). Peroxisome proliferator-activated receptor-gamma (PPARγ) coactivator-1 alpha (PGC-
1α) is one of them, which may play a role in PD pathogenesis as well. PGC-1α is a 
multifunctional transcriptional coactivator of nuclear respiratory factor 1 and 2 (NRF-1, -2), 
estrogen-related receptors (ERRs) and PPARs amongst others, and hereby regulates 
mitochondrial function and biogenesis (Knutti and Kralli, 2001).  
Analysis of human brain samples indicated that PD is associated with the increased 
methylation of PGC-1α promoter and the reduced expression of PGC-1α itself (Su et al., 
2015), and its downstream-regulated genes in the SN of PD patients (Zheng et al., 2010). 
Furthermore, possible associations of PGC-1α polymorphisms with PD risk, age of onset and 
longevity were described as well (Clark et al., 2011). Reduced expression of PGC-1α leads to 
enhanced α-synuclein oligomerization, too (Ebrahim et al., 2010), and accordingly, 
overexpression of PGC-1α produced neuroprotection against α-synuclein- and rotenone-
induced neurotoxicity (Zheng et al., 2010). 
Several PGC-1α isoforms were identified as a result of alternative splicing and alternative 
promoter usage (Martinez-Redondo et al., 2015). The proximal promoter of PGC-1α has been 
reported as an important key regulator in several neurodegenerative diseases, including PD 
(Su et al., 2015). With regard to alternative splicing, beside the full-length protein (FL-PGC-
1α), the N-truncated PGC-1α (NT-PGC-1α) isoform was discovered next, which is a shorter, 
but active isoform of PGC-1α (Zhang et al., 2009). Recent studies identified further different 
tissue-specific isoforms of PGC-1α, including central nervous system-specific isoforms 
(CNS-PGC-1α (Ruas et al., 2012; Soyal et al., 2012)). The novel CNS-specific isoforms 
originated from a new promoter located 587 kb upstream of exon 2 (Choi et al., 2013; Soyal 
et al., 2012). A recent study demonstrated that both PGC-1α reference gene and CNS-PGC-1α 
are downregulated in human PD brain and in experimental models with α-synuclein 
oligomerization and that the pharmacological activation or genetic overexpression of PGC-1α 
reference gene reduced α-synuclein oligomerization and toxicity (Eschbach et al., 2015). In 
contrast, the loss of that PGC-1α enhances the vulnerability of SN pars compacta 
dopaminergic neurons to α-synuclein toxicity (Ciron et al., 2015). These data suggest that 
PGC-1α downregulation and α-synuclein oligomerization form a vicious circle (Eschbach et 
al., 2015). Similarly to PD, certain mutations in amyotrophic lateral sclerosis inhibit the 
expression of CNS-specific isoforms, indicating this as a common finding in 
neurodegeneration (Bayer et al., 2017). 
St-Pierre et al. described that PGC-1α-deficient mice are more sensitive to MPTP toxicity 
compared to the controls (St-Pierre et al., 2006). Interestingly, the sub-chronic administration 
of MPTP to mice resulted in the significant elevation of PGC-1α expression in the striatum 
after 24 hours that was normalized following 72 hours (Swanson et al., 2013). This may 
represent an adaptive mechanism to neurotoxicity. Accordingly, the protective effect of PGC-
1α was demonstrated previously as well; pioglitazone- and resveratrol-induced activation of 
PGC-1α was protective against MPTP toxicity (Breidert et al., 2002; Dehmer et al., 2004). 
However, there is a seeming controversy with regard to the effect of genetically induced 
overexpression of PGC-1α on MPTP neurotoxicity. On the one hand, the transgenic 
overexpression of PGC-1α was proved to protective against MPTP (Mudo et al., 2012), on the 
other hand, the adenovirus vector-mediated overexpression of PGC-1α resulted in dopamine 
depletion in the SN (Ciron et al., 2012) and consequently enhanced susceptibility to MPTP 
(Clark et al., 2012). The clarification of this issue needs further studies. 
Evidence suggests the beneficial role of the stimulation of PGC-1α in neurodegenerative 
disorders. However, the CNS-targeted pharmacological stimulation is limited due to the poor 
penetration of the blood brain barrier (BBB) of the above-mentioned compounds, so 
preconditioning emerged as another option to achieve neuroprotection. It was previously 
demonstrated in light of our previous results that the acute administration of the selective 
complex II inhibitor 3-nitropropionic acid (3-NP) increased the expression of both FL- and 
NT-PGC-1α isoforms in the striatum of C57Bl/6 mice (Torok et al., 2015). As the available 
data are considerably limited with regard to the alteration of tissue-specific PGC-1α 
expression in the brain following MPTP administration, this study aimed at the examination 
of the expression levels of several PGC-1α isoforms in different brain regions following 
various MPTP treatment regimens. The hypothesis that low doses of MPTP may produce 
compensatory, protective alterations in the PGC-1α system was tested as well. 
 
2. Results 
2.1 Gene expression analysis 
Ninety minutes following the last MPTP injection of the acute treatment of MPTP, the FL-
PGC-1α and NT-PGC-1α expression significantly increased in the striatum (FL-PGC-1α: ctrl: 
0.97 (0.92-1.04), MPTP: 1.47 (1.21-1.83), p = 0.0048; NT-PGC-1α: ctrl: 0.44 (0.40-0.49), 
MPTP: 0.70 (0.56-0.78), p = 0.019), cortex (FL-PGC-1α: ctrl: 0.96 (0.91-1.06), MPTP: 1.23 
(1.15-1.43), p = 0.009; NT-PGC-1α: ctrl: 0.46 (0.43-0.48), MPTP: 0.69 (0.59-0.71), p = 
0.0012) and cerebellum (FL-PGC-1α: ctrl: 1.50 (1.27-1.90), MPTP: 2.40 (2.07-2.76), p = 
0.013; NT-PGC-1α: ctrl: 0.67 (0.48-0.86), MPTP: 1.21 (1.14-1.44), p = 0.009) (Fig. 1A, B). 
Furthermore, the MPTP-induced increases in the CNS-PGC-1α expression were also 
significantly larger in all investigated brain regions compared to the controls (striatum: ctrl: 
1.03 (0.88-1.11), MPTP: 1.38 (1.34-1.78), p = 0.0069; cortex: ctrl: 0.91 (0.80-0.98), MPTP: 
1.41 (1.24-1.42), p = 0.0048; cerebellum: ctrl: 1.51 (1.20-1.98), MPTP: 2.77 (2.34-3.17), p = 
0.019) (Fig. 1C). However, there was not any difference between the Ref-PGC-1α levels in 
the striatum (ctrl: 0.11 (0.10-0.12), MPTP: 0.11 (0.95-0.12)), cortex (ctrl: 0.11 (0.11-0.12), 
MPTP: 0.09 (0.08-0.10)) and cerebellum (ctrl: 0.21 (0.20-0.29), MPTP: 0.28 (0.24-0.29)) of 
MPTP-treated and control mice (Fig. 1D). 
One week following the last injection in the acute treatment regimen, there was not any 
significant change either in the FL-, NT-, CNS-, or in the Ref-PGC-1α levels between the 
control and the MPTP-treated animals in neither brain area (Fig. 2A-D). 
Furthermore, the low-dose 12-day MPTP-treatment did not influence the expression levels of 
FL-PGC-1α, NT-PGC-1α, CNS-PGC-1α and Ref-PGC-1α as well in neither brain region (Fig. 
3.A-D). 
 
2.2 HPLC measurement 
The dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) 
values in the respective control groups of the 3 treatment regimens were compared to each 
other, and there were no significant differences. Therefore the values in these control groups 
were pooled for further comparisons with the MPTP-treated groups. The MPTP 
administration caused significant reductions in the striatal DA (ctrl: 8.08 ± 0.50, MPTP: 4.36 
± 0.92, p = 0.0005), DOPAC (ctrl: 2.57 ± 0.21, MPTP: 0.44 ± 0.08, p = 3.78*10-8) and HVA 
(ctrl: 2.18 ± 0.12, MPTP 0.67 ± 0.11, p = 5.12*10-10) levels compared to control values 90 
min following its last administration in the acute treatment regimen (acute-1 day; Fig. 4). 
Moreover, a significant reduction in metabolite levels was also observed one week after the 
last injection in the acute treatment regimen (acute-7 days; Fig. 4) in the DA (ctrl: 8.08 ± 0.50, 
MPTP: 1.34 ± 0.43, p = 4.86*10-8), DOPAC (ctrl: 2.57 ± 0.21, MPTP: 0.76 ± 0.15, p = 7*10-
6) and HVA (ctrl: 2.18 ± 0.12, MPTP: 0.81 ± 0.13, p = 5.08*10-8) values in the striatum of the 
MPTP-treated mice compared to the control animals. However, chronic MPTP treatment 
resulted in significant reductions of only striatal HVA (ctrl: 2.18 ± 0.12, MPTP 1.40 ± 0.08, p 
= 0.0005) levels, striatal DA (ctrl: 8.08 ± 0.50, MPTP: 6.83 ± 0.48) and DOPAC (ctrl: 2.57 ± 
0.21; MPTP 1.99 ± 0.23) levels were not decreased significantly (Fig. 4). Seven days 
following the acute treatment regimen the DA levels significantly decreased compared to 
those data from samples obtained 90 min following the last MPTP injection in the acute 
treatment regimen (p = 0.039). 
 
3. Discussion 
PGC-1α is essential in normal mitochondrial functioning and its deficiency may contribute to 
neurodegeneration, while its stimulation demonstrated to be neuroprotective in certain models 
(Breidert et al., 2002; Dehmer et al., 2004; Eschbach et al., 2015; Mudo et al., 2012). 
Accordingly, the pharmacological induction of PGC-1α expression may come into account as 
a neuroprotective approach, but this possibility currently seems to be limited in light of the 
reduced BBB penetration of the potential pharmaceutical agents. 
The aim of the current study was the thorough assessment of the expression of PGC-1α 
isoforms in various brain regions following different MPTP administration regimens, 
including a low-dose chronic one possibly mimicking drug-induced preconditioning. 
Ninety minutes following the last MPTP injection of the high-dose acute treatment regimen of 
MPTP (75 mg/kg/day total dose) the expression level of FL-, NT- and CNS- PGC-1α 
isoforms increased significantly in the striatum, cortex and cerebellum. However, this 
elevation was diminished 7 days following the last MPTP injection in the acute treatment 
regimen. Torok et al. (Torok et al., 2015) demonstrated that the acute (90 min following a 
single dose injection of 100 mg/kg dose), but not the subacute (50 mg/kg twice daily for 5 
days) 3-NP treatment regimen induced the overexpression of FL- and NT- PGC-1α isoforms 
mainly in the striatum (3-NP is a rather selective striatal neurotoxin (Brouillet et al., 2005)) 
similarly to the results of the current study. Those findings were explained by the probably 
reduced neuronal adaptive capability of the striatum following the neurotoxic insult. The 
above-mentioned results of the current study may also be explained by the further propagation 
of the neurotoxic process following 7 days in the acute treatment regimen in light of the 
extent of decreases in the striatal DA levels. The elevation of PGC-1α expression especially 
that of the CNS-specific isoform, may indicate a short-term compensatory protective 
mechanism against the mitochondrial dysfunction induced by the complex I inhibitor MPTP. 
It is hard to interpret the increased expression of PGC-1α in the cerebellum, which is not 
primarily affected in MPTP toxicity. However, several lines of evidence indicated that MPTP 
neurotoxicity is not highly selective to dopaminergic neurons; in specific circumstances 
systemic MPTP administration resulted in Purkinje cell loss (Takada et al., 1993). The 
involvement of the cerebellum in disease mechanisms of different neurodegenerative 
disorders such as amyotrophic lateral sclerosis, Huntington’s disease (HD) and PD is 
frequently seen (Rees et al., 2014; Tan et al., 2016; Wu and Hallett, 2013). Furthermore, 
increasing evidence suggest that PGC-1α expression is associated with degenerative changes 
in the CNS, including in the cerebellum (Torok et al., 2015). It was hypothesized that the 
elevation of PGC-1α in the cerebellum is a compensatory mechanism against the energy 
deficit which may be an important factor underlying the relative resistance of cerebellar 
neurons against neurodegenerative processes in HD and in PD. 
The drug-induced preconditioning applying low-dose neurotoxic agents may stimulate 
neuroprotective mechanisms resulting in the amelioration of neurodegenerative process. This 
approach has already been demonstrated to be beneficial in case of 3-NP: the low-dose of 
toxin treatment increased the tolerance to ischemia and hypoxia in rats and gerbils (Horiguchi 
et al., 2003; Riepe et al., 1997; Wiegand et al., 1999). Although the exact mechanism in the 
background is not fully understood, the overexpression of free radical scavenging enzymes 
may be involved: acute 3-NP treatment activated superoxide dismutase (SOD) and catalase 
(CAT) in several brain areas (Binienda et al., 1998). Similarly, an increase in SOD activity in 
the glial cells of the striatum and SN was observed as well following MPTP treatment 
(Kurosaki et al., 2004). The preconditioning by MPTP is not intended to suggest future direct 
therapeutic approach, but rather aim at finding key players in the background which may help 
to do the best measures to alleviate the pathological alterations. The situation may be similar 
to ischemic preconditioning where the outcome in myocardial infarction may substantially 
depend on which medications were applied with an influence on preconditioning (Tomai et 
al., 1999). This may be especially important in light of the fact that environmental toxins 
could play a role in the pathogenies of idiopathic PD. The chronic low dose administration of 
MPTP in the current study neither resulted in significant DA depletion (i.e. neurotoxic effect 
at biochemical level), nor in any significant change of PGC-1α expression. These data suggest 
that drug-induced preconditioning by MPTP may not evoke apparent responses in the PGC-1α 
system. 
In conclusion the current study demonstrated that acute severe mitochondrial dysfunction 
initiated protection via elevating the expression of brain specific isoforms of mitochondrial 
master regulator PGC-1α. However, low-dose chronic administration of mitochondrial toxin 
MPTP did not induce those protective mechanisms with the involvement of PGC-1α. 
 
3. Experimental procedures 
3.1 Animals 
12-week-old C57Bl/6J male mice were used in this study. The animal strain was originally 
obtained from Jackson Labs (Jackson Laboratories, Bar Harbor, ME, USA). 
The animals were housed in cages and maintained under standard laboratory conditions with 
12-12 h light-dark cycle and free access to food and water. The experiments were carried out 
in accordance with the European Communities Council Directive (86/609/EEC) and were 
approved by the local animal care committee. 
 
3.2 Treatment and sample handling 
MPTP was dissolved in phosphate-buffered saline (PBS; pH adjusted to 7.4) and was 
administered intraperitoneally (i.p.). Animals were randomly divided into six groups (n = 7-8 
in each group). The first and second group received i.p. injection of 15 mg/kg body weight 
MPTP 5 times at 2 h intervals. The animals in the first group were deeply anesthetized with 
isoflurane (Forane; Abott Laboratories Hungary Ltd., Budapest, Hungary) and the brains were 
dissected ninety minutes following the last MPTP injection (acute treatment – acute (day 1) 
assessment), while animals in the second group were deeply anesthetized with isoflurane and 
the brains were dissected one week later (acute treatment - subacute (day 7) assessment). The 
mice in the third group were injected i.p. with 15 mg/kg body weight MPTP once a day for 12 
days (low-dose chronic treatment). Ninety minutes following the last injection the animals 
were euthanized via isoflurane overdose as well. The fourth, fifth and sixth groups served as 
the respective control groups, and were injected with 0.1 M PBS according to the above-
detailed treatment regimen. During the dissection process the brains were rapidly removed on 
ice and immediately halved at the midline. Following that, both hemispheres were further cut 
to obtain the striatum, cortex and cerebellum. Thereafter, these samples were stored at -80oC 
until the RT-PCR and HPLC analysis. 
 
3.3 RT-PCR Analysis 
The left striatum, cortex and cerebellum were homogenized and Trizol reagent was used to 
extract RNA according to the manufacturer’s protocol. The RNA was quantified 
spectrophotometrically, and the integrity of RNA was confirmed by gel electrophoresis using 
1% agarose gel. 1 μg of total RNA was reverse-transcribed applying random hexamer primers 
and reverse transcriptase according to the RevertAid First Strand cDNA Synthesis Kit 
protocol (Thermo Fisher Scientific Inc., Marietta, OH, USA). cDNAs were kept at -20oC until 
further use. 
Real-time PCR reactions were carried out in a 20 μl final volume. 
The following, previously published primers were used: for FL-PGC-1α, 5’-
TGCCATTGTTAAGACCGAG-3’ (forward) and 5’-TTGGGGTCATTTGGTGAC-3’ 
(reverse); for NT-PGC-1α, 5’-GGTCACTGGAAGATATGGC-3’ (reverse); for CNS-PGC-1α 
and Ref-PGC-1α, 5’-AATTGGAGCCCCATGGATGAAGG-3’ and 5’-
TGAGTCTGTATGGAGTGACATCGAGTG-3’ (both forward), and 5´-
TCAAATGAGGGCAATCCGTC-3´ (reverse), respectively (Chang et al., 2012; Soyal et al., 
2012). qRT-PCR reaction conditions were 95oC for 2 min, followed by 40 cycles of 95oC for 
10 s, and 60oC for 30 s. Target gene expression was normalized to the endogenous control 
gene 18S rRNA (Applied Biosystems, Carlsbad, CA, USA). The relative expression was 
determined using the 2-Ct method (Livak and Schmittgen, 2001). 
 
3.4 Dopamine measurement 
DA and its metabolites, DOPAC and HVA were measured by reversed-phase chromatography 
from the right striatum of the MPTP-treated and the control animals, applying an Agilent 
1100 high-performance liquid chromatography (HPLC) system (Agilent Technologies, Santa 
Clara, CA, USA) combined with a Model 105 electrochemical detector (Precision 
Instruments, Marseille, France) under isocratic conditions. The striata were weighted and then 
homogenized in an ice-cold solution (750 µl) containing perchloric acid (70% wt/wt), sodium 
metabisulfite (0.1 M), disodium ethylenediaminetetraacetate (0.1 M), distilled water and 0.25 
mM isoproterenol for 30 sec. The homogenate was centrifuged at 12,000 g for 10 min at 4oC. 
The supernatant was stored at -20oC until the analysis. The supernatants were measured with 
an Agilent 1100 high-performance liquid chromatography (HPLC) system (Agilent 
Technologies, Santa Clara, CA, USA) combined with a Model 105 electrochemical detector 
(Precision Instruments, Marseille, France) under isocratic conditions. In brief, the working 
potential of the detector was set at +750 mV, using a glassy carbon electrode and an Ag/AgCl 
reference electrode. The mobile phase containing sodium dihydrogenphosphate (75 mM), 
sodium octylsulfate (2.8 mM) and disodium ethylenediaminetetraacetate (50 μM) was 
supplemented with acetonitrile (10% v/v) and the pH was adjusted to 3 with phosphoric acid 
(85% w/w). The mobile phase was delivered at a rate of 1 ml/min at 40°C onto the reversed-
phase column (HR-80 C18, 80×4.6 mm, 3 µm particle size; ESA Biosciences, Chelmsford, 
MA, USA) after passage through a pre-column (SecurityGuard, 4 x 3.0 mm I.D., 5 µm 
particle size, Phenomenex Inc., Torrance, CA, USA)). 10 µl aliquots were injected by the 
autosampler with the cooling module set at 4°C. With regard to method validation, the 
following parameters are reported briefly. The LOD and LLOQ for the investigated 
compounds in the brain samples were 2 ng/ml and 10 ng/ml, respectively. With regard to 
precision, the relative standard deviation was ≤ 3.25% for the peak area responses and ≤ 
0.05% for the retention times. The recoveries ranged from 109 to 110%, 108 to 109% and 99 
to 102% for DA, DOPAC and HVA, respectively. 
 
3.5 Statistics 
All statistical analyses were performed with the use of the R software (R Development Core 
Team, 2002). The distribution of data populations was checked with the Shapiro–Wilk test, 
and Levene test was also performed for the analysis of the homogeneity of variances. In case 
of gene expression analysis, due to the necessity of a large number of comparisons of data, 
two-sample t-tests via Monte-Carlo permutation (with 10,000 random permutations) were 
applied for RT-PCR results. In case of HPLC analysis, all the data exhibited normal 
distribution and equal variances were assumed, and therefore ANOVA was used with 
Bonferroni post hoc comparison. The null hypothesis was rejected when the corrected p 
values were < 0.05, and in such cases the differences were considered significant. FL- and 
NT-PGC-1α levels of gene expression of all brain areas were calculated relative to the levels 
of FL-PGC-1α gene expression in the striatum, whereas the CNS- and Ref-PGC-1α 
expression levels of all brain areas were calculated relative to the level of CNS-PGC-1α 
expression in the striatum. Data with Gaussian or non-Gaussian distributions were plotted as 
means (± S.E.M.) or medians (and interquartile range), respectively. 
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Figure legends 
Fig. 1 The relative mRNA expression of PGC-1α isoforms in the striatum, cortex and the 
cerebellum of mice 90 min following acute MPTP intoxication. The FL-PGC-1α, NT-PGC-1α 
and CNS-PGC-1α levels were significantly increased in the striatum, cortex and the 
cerebellum of MPTP-treated mice. (A, B, C respectively). The Ref-PGC-1α expression did 
not change in any brain areas of MPTP-treated mice compared to the controls (D). Values are 
plotted as medians and interquartile range; *p < 0.05, **p < 0.01; MPTP MPTP-treated; str 
striatum, ctx cortex, crb cerebellum. 
Fig. 2 The relative mRNA expression of PGC-1α isoforms in the striatum, cortex and the 
cerebellum of mice 7 days following acute MPTP intoxication. The expression levels of the 
PGC-1α isoforms did not change in any brain areas of MPTP-treated mice (A-D). Values are 
plotted as medians and interquartile range; MPTP MPTP-treated; str striatum, ctx cortex, crb 
cerebellum. 
Fig. 3 The relative mRNA expression of PGC-1α isoforms in the striatum, cortex and the 
cerebellum of mice following a 12-day treatment with low-dose MPTP. The expression levels 
of the PGC-1α isoforms did not change in any brain areas of MPTP-treated mice (A-D). 
Values are plotted as medians and interquartile range; MPTP MPTP-treated; str striatum, ctx 
cortex, crb cerebellum. 
Fig. 4 Striatal dopamine, DOPAC and HVA concentrations of MPTP-treated mice in 3 
different treatment regimens. Ninety minutes (acute-1d) and 7 days (acute-7d) following acute 
MPTP intoxication, DA, DOPAC and HVA levels significantly decreased in the striatum 
compared to the controls. The chronic (12 day) low-dose MPTP treatment did not influence 
the striatal level of DA and DOPAC, only HVA levels were significantly decreased. Values 
are plotted as means ± S.E.M; ***p < 0.001; DA dopamine, DOPAC 3,4-
dihydroxyphenylacetic acid, HVA homovanillic acid 
